Children's Cancer CoLab
Accelerating research, innovation and collaboration

IMPACT PROGRAM FUNDING GUIDELINE
NEXT GENERATION THERAPIES

Items	Details
Funding Round	FY26
Type of Opportunity	Open, competitive funding call
Contact	programs@cccolab.org.au
EOI Submission Period	September 8th - October 17th (2025)
Full Application Submission Period	January 19th – February 29th (2026)
Anticipated funding commencement	July 1st, 2026
Grant Amount	$1,500,000 available for this funding call
Grant Term	Up to three (3) years
Number of Grants	Grants of varying size and duration will be considered, but applicants should be mindful that the funding available is *intended to support a minimum of three projects in total*.

1. About the Children's Cancer CoLab

The Children's Cancer CoLab (CoLab) is a non-profit organisation dedicated to bringing together many of Australia's brightest childhood cancer researchers and clinicians from across institutions and disciplines to fast-track discoveries for childhood cancer patients.

Our collaborative approach has already united nine of Victoria's leading research, clinical, and academic institutions to breaking down traditional silos to achieve what no single organisation could achieve alone, ultimately driving improved outcomes for young cancer patients in Victoria and beyond.

CoLab's vision, mission, and values reflect our forward-thinking approach and commitment to collaboration. Central to our purpose is the belief that all children should not only survive cancer but also thrive in life after treatment. CoLab stands as a leader in children's cancer research and innovation funding, championing both scientific excellence and the lived experiences of survivors and their families. By fostering a culture of shared expertise and collective impact, we strive to set new standards for research, clinical care, and survivorship in paediatric oncology.

Our Vision

Every child with cancer will survive and thrive.

Our Mission

To improve outcomes for our youngest cancer patients by accelerating collaborative research and innovation into the clinic.

Our Values

Courage
Community
Compassion
Collaboration

1.1. Our Impact Programs

CoLab's Impact Programs encompass three research-focused areas, plus two dedicated themes for capacity and capability building in paediatric oncology. These efforts aim to address critical gaps in access to innovative therapies, treatment safety, survivorship, workforce capacity, and research infrastructure.

1.2. Our Approach for Impact Program Funding

CoLab operates as a strategic funding body, focused on maximising the impact of investment in childhood cancer research and innovation. CoLab's funding model is designed to support collaborative, multidisciplinary initiatives that address the most pressing needs in paediatric oncology. By bringing together leading researchers, clinicians, and institutions, we aim to accelerate the translation of research discoveries into real-world improvements in care and outcomes for young cancer patients.

Applicants should be aware that CoLab's Impact Program funding approach is underpinned by five core principles that are intended to ensure that funded activities lead to meaningful, measurable improvements for young cancer patients and their families:

- **Prioritising needs based on patients' voices** – Engage with young cancer patients and families to identify unmet needs and setting priorities to inform funding decisions.
- **Driving impact through strategic and tactical action** – Commit to outcomes-driven funding, ensuring resources are strategically targeted to achieve the greatest impact through prioritised, collaborative investment in areas of highest need.
- **Transparent and competitive funding process with accountability** – Implement open, competitive grant process with robust scientific review to evaluate each proposal's potential for success and impact in childhood cancer research and care.
- **CoLaborative synergy for greater impact** – Foster interdisciplinary, multi-site collaboration by encouraging researchers and clinicians to leverage diverse expertise across disciplines and locations, broadening the impact and scope of research outcomes.
- **Milestone-based funding model** – Employ a funding model the incorporates milestone-based awards with embedded critical review criteria that combines rigorous outcome measures with dynamic resource allocation.

2. Objectives of the Next Generation Therapies Impact Program

Advancement in treatment have significantly increased childhood cancer survival rate to above 80% over the last few decades. Yet despite these remarkable gains, a subset of malignancies continues to devastate young patients and their families with minimal therapeutic progress, examples include:

- Children with diffuse intrinsic pontine glioma typically survive 8-11 months after diagnosis, with only 10% reaching two years and just 2% surviving five years.

- Survival rate for advanced paediatric sarcomas remains poor, with five-year survival typically ranges from 15% to 30% for children with metastatic or recurrent disease.
- For high-risk neuroblastoma, about 50% to 60% of children with newly diagnosed diseases survive beyond five years, but this rate drops to 24% to 30% for those with advanced or relapsed disease despite intensive, multimodal treatment.

The therapeutic challenges of hard-to-treat cancers arises from fundamental biological and developmental differences that set them apart from adult cancers. As a result, treatments developed for adults are often ineffective in children, highlighting the critical need for dedicated research efforts in paediatric oncology. Additionally, the rarity of childhood cancers, sometimes with fewer than 50 new cases annually in Australia for ultra-rare subtypes, makes traditional industry-led drug development economically unattractive, leading to major gaps in treatment options.

Focusing research funding on the most treatment-resistant childhood cancers is both an ethical imperative and a strategic opportunity aligned with CoLab's objective to advance breakthrough treatments in paediatric oncology. These cancers embody the greatest unmet medical needs in the field and, because they are often genetically simpler than adult malignancies, present a unique opportunity for discoveries that can fundamentally improve our understanding of cancer biology and development.

The program aims to generate the crucial preclinical and translational evidence required to de-risk and accelerate future investment and development, paving the way for clinical advances that may transform outcomes for children with the hardest-to-treat cancers.

2.1. Program objective

The Next Generation Therapies Impact Program seeks to identify or develop breakthrough treatments specifically designed for the hardest-to-treat childhood cancers, by harnessing cutting-edge technologies in the identification of novel and actionable therapeutic targets, to improve survival rates for young cancer patients.

2.2. Intended outcomes

The program aims to identify new therapeutic targets for the most challenging childhood cancers, with the potential to move these discoveries toward clinical translation. In the short term, the program aims to facilitate the development of safe and effective therapies, with the goal of enabling researchers to secure future or additional funding to continue or expand upon these research outcomes. Over the long term, the expected impact is to achieve market approval for effective new therapies and to improve the survival rates for children with high-risk cancers.

2.3. Scope and scale of the project

The program welcomes projects of all sizes and stages of development, from early-stage innovation and discovery research through to late-stage validation in advanced preclinical models or clinical studies. There are no restrictions on the scale of the proposed research - applicants are encouraged to define a project scope that is appropriately matched to the research question, anticipated outcomes, and intended impact.

Proposals should clearly articulate the rationale for the chosen scale, outlining how the planned activities advance the project toward its next key milestone(s). The budget should be commensurate with the proposed scope of work, with all costs justified in terms of delivering the stated objectives. Funding requests will be evaluated by the strength of the value proposition and the alignment of the budget with the project's ambitions, stage of maturity, and potential for impact.

2.4. Milestone-based funding model for accountability

In addition to supporting projects across all scales and stages, the program prioritises initiatives that will generate a compelling evidence base needed to increase their competitiveness for the traditional, larger-scale funding (e.g. government and industry). By providing targeted resources for evidence building, we aim to strengthen the scientific and strategic foundation of innovative ideas so they can progress toward clinical translation or substantial external investment.

Projects supported through this program - whether at early discovery, preclinical validation, or clinical investigation stages - are expected to be structured around clearly defined milestones and measurable deliverables. These milestones serve as agreed reference points for tracking progress, facilitating open communication with the project team, and ensuring activities remain aligned with objectives. They are intended as flexible review opportunities to discuss progress, assess emerging data, and adjust plans where needed, rather than rigid go / no-go decision gates.

2.5. Incremental funding mechanism to support innovation

Projects demonstrating strong progress against milestones may be invited to fast-track proposals for subsequent funding phases, outside of standard annual cycles. Conversely, if milestones are not achieved, or if new data suggest a revised approach is warranted, applicants are encouraged to present alternative strategies for review by the Scientific Advisory Committee. In rare instances where milestones are not met and no suitable alternative pathway can reasonably deliver the intended outcomes, the project will be terminated to ensure responsible and effective use of program resources.

This incremental, milestone-based funding mechanism is central to our approach: it rewards demonstrated progress, supports ongoing innovation, and ensures that resources are concentrated on the most promising projects - preparing them for support required to reach clinical translation or attract substantial external investment.

3. Research Priorities and Focus Areas

The following research priorities and focus areas are categorised to highlight current needs and emerging directions in the development of new treatments for the deadliest paediatric cancers with limited effective therapies, including high-grade gliomas, medulloblastoma, diffuse intrinsic pontine glioma, metastatic sarcomas, and treatment-resistant or relapsed leukaemia.

Whilst the research project must have direct contributions to discovery, translational and/or clinical research in the paediatric oncology field, these categories are intended to provide examples rather than a comprehensive list. However, research that thoughtfully combine scientific novelty, strong rationale, and clear translational potential will be highly regarded. Potential areas of research include:

- **Therapeutic target discovery and validation**: Identification and validation of therapeutic targets through integrated multi-omics analysis, experimental confirmation of their functional roles in cancer, and evaluation of their safety and relevance for paediatric patients.
- **Modality-optimised therapeutic design**: Design and delivery of paediatric-appropriate therapeutics through advanced engineering of small molecules and biologics, innovative formulation strategies, and next-generation delivery platforms tailored to developmental needs and pharmacological constraints.
- **Therapy optimisation and combination strategies**: Mechanism-informed treatment strategies, including rational drug pairings, resistance-bypass regimens guided by tumour evolution, and radiotherapy approaches that enhance tumour targeting while protecting healthy tissue.
- **Immune and microenvironment modulation**: Advancement of paediatric immunotherapy through engineered cellular platforms, novel immune activators and checkpoint combinations, microenvironmental reprogramming strategies, and oncolytic virus approaches that enhance anti-tumour immune responses.
- **Predictive technologies and precision implementation**: Enhancement of precision paediatric oncology through liquid biopsy and minimal residual disease monitoring, AI-driven decision support integrating multi-modal data, and adaptive trial designs that accelerate access to promising therapies for ultra-rare patient cohorts.
- **Biomarker development and diagnostic innovation**: The use of biomarkers to monitor treatment response and guide therapy adjustments, and the identification of prognostic and predictive markers that inform clinical outcomes and therapeutic choices.

- **Translational readiness and pre-clinical-to-clinical bridging**: Development of robust and ethically aligned paediatric oncology interventions through rigorous preclinical testing, harmonised regulatory planning, and collaborative co-design with key stakeholders to ensure feasibility, safety, and rapid clinical adoption.

4. Preparing Your Application

This document serves as the funding guideline for this funding opportunity, detailing the objectives, eligibility considerations, and evaluation criteria relevant to the Next Generation Therapies Impact Program. Applicants are strongly encouraged to carefully review this funding guideline in preparation of their application to ensure a thorough understanding of process and requirement. For any questions not addressed within this guideline, please contact us at programs@cccolab.org.au.

4.1. Applicant / Application eligibility considerations

- Applications must demonstrate clear relevance and impact for paediatric oncology, ensuring that the research outputs and outcomes are applicable for the unique biology and challenges of paediatric oncology.
- The lead investigator (main applicant) must hold a formal appointment or position at one of the Consortium Partners at the time of application and for the duration of the grant funding period.
    - Secondment or honorary appointments may be accepted, provided they are recognised by the Consortium Partner institution and allow the applicant to undertake the proposed research activities.
- An individual can only be listed as the lead investigator (main applicant) for one application for each Impact Program funding round. However, there are no restrictions on the number of applications in which a particular individual can be listed as a team member for the same funding round.
- Multiple applications from each Consortium Partner (as the administering institution) will be accepted for each funding round.
- Applications must involve collaboration with researchers / clinicians from another Consortium Partner as part of the project team.
    - This collaboration may include contribution of time, resources or expertise – either supported by CoLab funding or provided as in-kind.
    - Applications that thoughtfully allocate funding across multiple institutions will be viewed highly favourable during assessment.
    - For applications where such collaboration is not feasible or appropriate, such as smaller projects, please contact the team at programs@cccolab.org.au for further instruction to complete the application online.
- Applications from primarily adult oncology-based research groups must include at least one paediatric oncology researcher and/or clinician as a project team, and this collaboration must be formalised with the nominated paediatric oncology researcher and/or clinician receiving funding for their participation in the project activities.
- Applications should support activities within Victoria. Payment to third parties outside Victoria will only be considered on a case-by-case basis if the necessary activity or service is not available locally or cannot be sourced in Victoria at a fair cost or value.
- Applicants may include both existing and new roles within their project teams. Applicants are strongly encouraged to propose new roles that will contribute fresh expertise, perspectives, or capabilities to the project team. Preference may be given to applications that demonstrate how newly created roles will enhance project outcomes and advance the overall aims of the funding initiative.
    - *Existing Role: A position that was established and filled prior to the project start date.*
    - *New Role: A position created specifically to support the objectives and activities of the funded project; recruitment or appointment could occur on or after the project start date (including a previously employed individual who has transitioned into the newly funded position).*

4.2. Eligible & ineligible activities considerations

Eligible Activity	Ineligible Activity
• Research project with a clearly defined scope and objective, a strong rationale demonstrating the project's significance and relevance, well-formulated hypothesis, and a defined approach with milestones for testing. • Discovery and translational research projects that support the development of novel treatments, or repurpose of currently approved treatments, for paediatric cancer types with low survival rates. • Clinical research projects that aim to improve survival outcomes for paediatric cancer types with low survival rate. • Directly incurred costs and associated expenditure that are essential to undertaking and supporting the planned research, and that contribute to achieving the research objectives and intended outcomes. • Salary support for individuals who are directly involved in delivering research activities and contributing to the project's outputs and deliverables. Salaries will be covered in accordance with their standard institutional rates. Compensation is determined by each individual's experience and qualifications and includes on-costs, capped at a maximum allowable rate of 20%. • Salary support for individuals is subjected to the condition that each individual's total Full-Time Equivalent (FTE) commitment, inclusive from this funding opportunity and all other funding sources, must not exceed 1.0 FTE (equivalent to 100% effort) during the grant funding period. It is the responsibility of both the personnel and the administering organisation to monitor and certify that the combined FTE commitments from all sources of support do not exceed this threshold at any time. • *(Deprioritised) Investigator-initiated national or international clinical studies not led by Victorian sites.*	• Research project that may be applicable to paediatric oncology but does not include any testing or validation with paediatric cancer models or paediatric patients. • Research project that lacks a clear hypothesis and defined expected outcomes. • Activities where the primary goal is to develop resources or platforms for hypothesis-driven research activities. • Research proposal consisting of multiple projects, each with its own distinct goals and aims. • Activities and salary support for individuals that have already received funding for the same outputs and outcomes from other funding source. • Industry-sponsored national or international clinical studies. • Salaries for individuals who are not directly contributing to the research outputs and deliverables. • Indirect / overhead cost such as infrastructure, utilities and administration costs

4.3. Application outline

The table below provides an overview of the key information and details required for both the EOI and full application submissions. Please note that this summary is intended as general guidance only; applicants should always refer to the official template and instructions available on the CoLab Grant Portal (https://cccolab.grantplatform.com) to ensure all requirements are met and the most up-to-date details are included.

Application Sections	EOI	Full Application
Project title	Long and short project title	
Applicant details	• Information on the lead investigator (of this application) • Information on the administering institution – including contact information for the research office • Eligibility confirmation	
Consumer engagement & lay summary	• Description of the unmet need in paediatric oncology. • Research project summary in plain language.	• Provide a detailed description of how consumers (patients, survivors, families, or carers) have been or will be engaged in the project's design and delivery. • Clearly state the consumer-identified need and anticipated benefits or outcomes for the childhood cancer community.

Application Sections	EOI	Full Application
	• Explain the relevance and potential benefit of the research. • Outline any initial or planned consumer involvement in the project design. *Max. 750 words*	• Describe plans for how research outputs will be made accessible and inclusive for diverse audiences. • Response to any consumer reviewer feedback from the EOI stage. *Max. 2 pages*
Impact & Benefit to Paediatric Oncology	• Statement of alignment with hardest-to-treat childhood cancers (high mortality / limited options). • Identification of significant research gaps addressed. • Project overview, research question, and intended paediatric oncology focus. • Summary of pathway to impact: how the proposal could change diagnostics, treatments, or outcomes. *Max. 750 words*	• Overview of the challenge in hardest-to-treat childhood cancers and alignment with the unmet need in paediatric oncology. • Detailed description of anticipated translational and clinical significance. • Explanation of how the work addresses critical gaps and leads to better outcomes. • Pathway to real-world benefit for patients • Evidence that the project addresses consumer-identified needs. • Strategy for communicating outputs in accessible and inclusive ways. *Max. 1 page*
Scientific Innovation, Research Design & Methodology	• Background and description of the unmet need being addressed. • Outline the key scientific rationale, hypothesis, aims and novel aspects of the project. • Brief description of proposed methods and innovative approaches. • Outline of any initial or planned consumer involvement in the project design. *Max. 750 words*	• Current knowledge gaps and scientific need • Literature and evidence supporting project rationale • Hypothesis and project aim(s) • Description of how project offers new concepts or approaches • Detailed study design, methodology, and analysis plan • Integration of novel methods/technologies, justification of technical choices. • Plans for ensuring reproducibility, addressing confounding, and data management. • Detail on consumer co-design or advisory input • Ethical considerations and plans for necessary approvals • Steps towards ensuring the practical feasibility and anticipated obstacles. • Risk assessment, including mitigation strategies *Max. 6 pages*
Team Capacity & Expertise	• Short biographies of lead investigator and key project team members. • Description of relevant track record and any prior collaborative experience. *Max. 500 words*	• Full description of the project team credentials and contribution of the investigators to the sector. • Past successes relevant to project aims – including up to 10 key publications. • Evidence of prior effective collaboration • Outline of planned training and mentorship activities that will support the professional growth and meaningful engagement of junior team members, with a focus on early-career researcher development • CV for lead investigators and project team members *Max. 2 pages excluding the CVs. CVs can be uploaded as additional files and should be limited to a max. one (1) page per team member collated into a single PDF.*
Project timeline,	• Major milestones and their anticipated duration / completion time – including at	• Gantt chart or detailed timeline with major milestones and deliverables

Application Sections	EOI	Full Application
milestone & deliverables	least two (2) critical review points.	• Description of the two (2) critical review points that are appropriate for the proposed activities, and provide details on the expected outcomes / deliverables to be achieved at the review points – these review points should take into consideration feedback received from the EOI stage.
Project budget	• High-level project budget that outlines estimated annual / total costs by category (e.g. personnel, consumables etc).	• Detailed, itemised budget and justification for each cost using provided template. • Description of access to facilities, equipment, services and institutional resources. • Description of any in-kind support or leveraged funding from other funding sources.
Collaboration & Partnership	• Identification of all participating institutions / key contributors. • Brief outline of multidisciplinary and/or cross-institutional elements. • Summary of anticipated resource sharing or network benefits. • For projects that do not have any collaboration, a justification of why the project doesn't require any collaborators. *Max. 300 words*	• Detailed description of all collaborators and their contribution to the project, whether it is allocated time on the project or provision of resources – this could be funded by CoLab or provided as in-kind support. • Multidisciplinary team composition. For each team member, clearly specify their individual role and expected contribution to the project. • Mechanisms for resource sharing and/or building a lasting collaborative network. *Max. 500 words.*
Response to reviewer feedback	Not applicable	• Clear and concise response to each reviewer comment, outlining how feedback has been addressed or incorporated into the full application, or explaining the rationale if certain suggestions were not adopted. *Max. 2 pages*
Declaration of resources & institutional support	• (Automated) Confirmation from the institution's research office to acknowledge EOI submission.	• Letters of support from institutions and consumers (as available). • Acknowledgement / confirmation from the institution's research office to demonstrate support of full application submission.

For full application, applicants are required to prepare their responses in accordance with the standard formatting instructions:

- Use Times New Roman or Arial font with a minimum of 11 pt font size.
- Maintain minimum of 2 cm margins on all sides.
- Ensure each section is clearly labelled with headings.
- Figures, tables, and charts should be readable when printed on standard A4 paper and count toward page limits where applicable.
- Upload the document in PDF format.

4.4. Application evaluation criteria

EOIs and full applications will be assessed by a multidisciplinary panel with relevant subject matter expertise in paediatric oncology research and care, alongside representatives from childhood cancer survivors and/or families. Assessments will be based on pre-defined evaluation criteria outlined in the table below, with weighting of each criterion adjusted between the EOI and full application stages to reflect the level of detail and information available to reviewers at each stage.

Evaluation Criteria	Sub-Criteria	EOI Weighting	Full Application Weighting
Consumer Reviews	• Addressing an important, unmet need for childhood cancer patients and survivors. • Relevance to childhood cancer patients, survivors, families or carers. • Anticipated benefits that are meaningful to patients and their support network. • Consumer engagement in design and development of research. • Accessibility and inclusivity of research outputs and outcomes. • Realistic pathways for applying research findings into practice and potential for real-world adoption.	20%	20%
Impact & Benefit to Paediatric Oncology	• Clear alignment of research aims with paediatric cancers that have poor survival rates and limited therapeutic options. • Targets significant gaps where current therapies and understanding are limited. • Realistic pathway for research findings to inform new or improved diagnostic or therapeutic strategies. • Well-articulated statement describing the specific potential benefits to paediatric oncology, addressing significant challenges or priorities in childhood cancer. • Application of novel technologies or methods that clearly improve upon existing standards in the field. • Accessible communications of outputs.	30%	20%
Scientific Innovation, Research Design & Methodology	• Clear description of new concepts or perspectives that could substantially shift current understanding in paediatric oncology. • The proposal is underpinned by a clear, logical rationale that is well-supported by current evidence and addresses a defined scientific need. • A clearly defined and appropriate study design, robust data collection/analysis, and methodological rigour, including strategies for reproducibility and control of confounding factors. • Effective use of novel or improved research methods, ensuring that any technical innovations are well-integrated and justified within the project. • Thoughtful approach to ethical considerations, with plans for relevant approvals and the protection of participant welfare as applicable. • Practicality and feasibility of the project plan, including sufficient detail on how proposed methods will enable translation towards impact, especially for the hardest-to-treat childhood cancers. • Inclusion of a risk assessment and mitigation strategies, showing awareness of potential challenges and plans to address them for successful completion of the research. • Adequate resources and infrastructure requirements are fully addressed, demonstrating that the team has access to all necessary equipment, facilities, and personnel. • Confirmed institutional support and capacity regarding infrastructure, commitment and capabilities as required.	20%	25%
Team Capacity & Expertise	• The principal investigator demonstrates strong qualifications and relevant experience, reflecting a proven ability to lead and deliver high-quality research in related fields. • The research team collectively possesses deep expertise in paediatric oncology, as well as strong scientific, clinical, or other discipline-specific knowledge relevant to the proposed project. • Inclusion of robust training and mentorship opportunities, specifically fostering the involvement and development of early-career researchers in the project.	10%	15%

Evaluation Criteria	Sub-Criteria	EOI Weighting	Full Application Weighting
	• Leadership capabilities and project management skills are well-evidenced, indicating the team's capacity to coordinate, manage, and successfully complete complex research initiatives. • Demonstrated expertise and track record relevant to the proposed research area, supported by prior publications, successful projects, or clinical experience in high-mortality paediatric cancers. • Evidence of successful previous collaborations, demonstrating the team's ability to work effectively across organisational boundaries.		
Budget Suitability & Project Timeline	• Clearly justified budget that demonstrates cost-effectiveness, ensuring each expense is appropriate and necessary to achieve the research objectives. • Realistic and well-structured project timeline, with clearly identified key milestones and deliverables that enable effective progress tracking, including achievable phases with appropriate duration and sequence of each project component.	5%	10%
Collaboration & Partnership	• Collaboration with researchers / clinicians from another Consortium Partner is mandatory, where allocation of funding across multiple institutions is highly encouraged and regarded as evidence of strong shared leadership and resource integration. • Establishment of a multidisciplinary team composition that actively brings together expertise from different fields, including collaborators who have not previously worked in paediatric oncology, to introduce cross-disciplinary perspectives and fresh approaches. • Well-articulated resource sharing and network building activities to demonstrate how their collaboration maximises impact.	15%	10%

5. How to Apply

5.1. Application process

The application process for the Next Generation Therapies Impact Program funding opportunity involves two stages: an Expression of Interest (EOI) and a full application:

- EOIs are reviewed by a dedicated panel comprising subject matter experts from our Scientific Advisory Faculty, each bringing relevant expertise, alongside representatives from our Patient and Family Advisory Committee (PFAC). This panel shortlists applicants who are then invited to proceed to the full application stage.
- The full applications are evaluated by the Scientific Advisory Committee and representative PFAC members to make the final funding recommendation.

Whilst the evaluation criteria remain consistent across both the EOI and full application stages, different weighting will be applied at each stage to reflect the varying level of information available for review and to ensure appropriate assessment. The review panels will score applications individually before meeting to discuss and reach consensus on the highest-ranking submissions. Please refer to Section 4.4 for detailed evaluation criteria and their respective weighting at each stage.

5.2. Application timeline

Event / Action	Year	Date
Expressions of Interest (EOI) submission period (6 weeks)	2025	September 8th to October 17th
EOI submission closes		**October 17th**
EOI assessment by the review panel		October to November
Applicant notified of EOI assessment outcome – shortlisted applicants will receive an invitation to submit a full application		2nd week of December
Full application submission period (6 weeks)	2026	January 19th to February 27th
Full application submission closes		**February 27th**
Full application assessment by the review panel		March to April
Applicant notified of full application assessment outcome & commencement of grant agreement review		May
Anticipated funding commencement		July 1st

5.3. Application submission

Applications must be prepared in accordance with the structure outlined in Section 4.3, and submitted electronically using the **CoLab grant portal** (https://cccolab.grantplatform.com) an online grant management system.

Applicants who are not yet registered must do so before they commence their application.

Applications must be submitted by the closing date of the funding call. Late submission will not be considered. Upon submission, you will receive a confirmation of receipt. Applicants are strongly encouraged to retain a copy of their application for their own records.

5.4. Contact information

For any questions or further information, please contact our team at programs@cccolab.org.au.